GI
YMAB

GAMMA Investing’s Y-mAbs Therapeutics YMAB Stock Holding History

GAMMA Investing’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33
Closed -$258 – 3889
2024
Q4 		$258 Sell
33
-7
-18% -$85 ﹤0.01% 3680
2024
Q3 		$526 Buy
40
+35
+700% +$444 ﹤0.01% 3386
2024
Q2 		$60 Sell
5
-21
-81% -$284 ﹤0.01% 3420
2024
Q1 		$423 Buy
+26
New +$350 ﹤0.01% 3130

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

GAMMA Investing's YMAB Position: Q1 2025 in Review

GAMMA Investing sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 33 shares — an estimated $258 sold.

GAMMA Investing first reported a position in YMAB in Q1 2024 and held it in 4 quarters. The position peaked at $526 in Q3 2024. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • GAMMA Investing reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • GAMMA Investing sold 33 Y-mAbs Therapeutics shares in Q1 2025, an estimated $258.
  • GAMMA Investing first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 4 quarters.
  • GAMMA Investing's Y-mAbs Therapeutics position peaked at $526 in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on GAMMA Investing's 13F filing for Q1 2025, filed 7 Apr 2025.